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COMPOUNDS THAT SUPPRESS CANCER
CELLS AND EXHIBIT ANTITUMOR
ACTIVITY

the binding to the Stat3 SH2 domain(18, 19), per the X-ray
crystal structure of the Stat3 homodimer (26). One of those
leads, S3I-201 (18) had previously been shown to exert antitumor effects against human breast cancer xenografts via
mechanisms that involve the inhibition of aberrant Stat3.

CROSS-REFERENCE TO RELATED PATENT
APPLICATIONS
This application is a National Phase Application of International Application No. PCT/US2010/001021 filed Apr. 5,
2010, which claims priority to U.S. Provisional Patent Application No. 61/246,695 filed Sep. 29, 2009 and to U.S. Provisional Patent Application No. 61/166,865 filed Apr. 6, 2009,
each of which is incorporated in its entirety by this reference.
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH OR DEVELOPMENT
This invention was made with govermnent support under
Grant Nos. ROI CAI06439 and ROI CAl28865 awarded by
the National Institutes of Health. The govermnent has certain
rights in the invention.
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SUMMARY OF THE INVENTION

FIELD OF THE INVENTION
The present invention relates to the field of drug development and, more particularly, to compounds that inhibit cancer
cells.

With the foregoing in mind, the present invention advan25

BACKGROUND OF THE INVENTION
30

Signal transduction proteins have increased importance in
carcinogenesis and tumor formation and represent attractive
targets for the development of novel anticancer therapeutics.
The Signal Transducer and Activator of Transcription
(STAT) family of proteins are cytoplasmic transcription factors with important roles in mediating responses to cytokines
and growth factors, including promoting cell growth and differentiation, and inflanimation and immune responses (1,2).
Normal STATs activation is initiated by the phosphorylation
of a critical tyrosine residue upon the binding of cytokines or
growth factors to their cognate receptors. The phosphorylation is induced by growth factor receptor tyrosine kinases, or
cytoplasmic tyrosine kinases, including Janus kinases or the
Src family kinases. While pre-existing dimers have been
detected (3,4), phosphorylation is observed to induce dimerization between two STAT monomers through a phosphotyrosine interaction with the SH2 domain. In the nucleus, active
STAT dimers bind to specific DNA-response elements in the
promoters of target genes and regulate gene expression.
It is now well established that aberrant activation of the
member of the family, Stat3 contributes to malignant transformation and tumorigenesis. Aberrant Stat3-mediated oncogenesis and tumor formation is due in part to the transcriptional upregulation of critical genes, which in turn lead to
dysregulation of cell growth and survival, and the promotion
of angiogenesis (2, 5-11) and tumor immune-tolerance (12,
13 ). Thus, targeting of aberrant Stat3 signaling would provide
a novel strategy for treating the wide variety of human tumors
that harbor abnormal Stat3 activity.
The critical step of dimerization (14) between two monomers within the context of STAT activation presents an attractive strategy to interfere with Stat3 activation and functions
and this approach has been exploited in prior work (15-25).
Leading agents from those earlier studies have been explored
for rational design in conjunction with molecular modeling of

In the present study, key structural information from the
computational modeling of S3I-201 bound to the Stat3 SH2
domain facilitated the design of novel analogs of which S3I201.1066 and S3-201.2096 show improved Stat3-inhibitory
activity. Both S3I-210.1066 and S3I-201.2096 inhibit Stat3
activity with IC 50 values of35 and 45 µM, respectively. This
disclosure presents evidence that S3I-201. I 066 interacts with
the Stat3 protein and disrupts Stat3 binding to its cognate
pTyr peptide of receptors. Furthermore, S3I-201.1066
induces antitumor cell effects selectively in malignant cells
harboring aberrant Stat3 and antitumor response in vivo in
human breast xenografts.
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tageously provides a useful expansion of several prior studies
that have provided the proof-of-concept for the therapeutic
effects of Stat3 inhibitors in human tumors. The molecular
modeling of the phosphotyrosine (pTyr)-SH2 domain interaction in Stat3:Stat3 dimerization, combined with in silica
structural analysis of the previously reported Stat3 dimerizationdisruptor, S3I-201, has furnished a diverse set of analogs.
Herein we disclose that compounds S31201. I 066 and S3I201.2096 selectively inhibit Stat3 DNA-binding activity in
vitro, with IC 50 values of35 and 45 µM, respectively. In vitro
biochemical and biophysical studies show that S3 I-201.1066
interacts with Stat3 or the SH2 domain, with an affinity (KD)
of 2.74 µM, and disrupts Stat3 binding to the cognate pTyrpeptide motif, with an IC 50 value of 23 µM. Accordingly,
S3I-201.1066 blocks Stat3 association with the epidermal
growth factor (EGF) receptor in EGF-stimulated fibroblasts
or in cancer cells, consequently inhibiting Stat3 phosphorylation, nuclear translocation and transcriptional activity,
without affecting the Er]<MAPK pathway.
Furthermore, treatment with S3I-201. I 066 selectively suppressed the growth, viability, survival and malignant transformation of human breast (MDA-MB-231) and pancreatic
(Panc-1) cancer lines and v-Src-transformed mouse fibroblasts harboring aberrant Stat3, and down-regulated the
expression ofknown Stat3-regulated genes, including c-Myc,
Bcl.xL, the matrix metalloproteinase 9, and VEGF. Importantly, treatment with S3I-201.1066 induced strong tumor
regression in xenografts of the human breast cancer line
MDA-MB-231.
Taken together, the present disclosure identifies compounds S3I-201.1066 (Formula I) and S3I-201.2096 (Formula 2) as selective Stat3 binding agents that block Stat3
association with cognate receptor pTyr motifs, Stat3 phosphorylation and nuclear translocation, Stat3 transcriptional
function, and consequently induced Stat3-specific antitumor
cell effects in vitro and antitumor response in vivo.
Accordingly, the present disclosure provides a novel compound, analog of S31-201, according to Formula I, as set
forth below and in FIG. 1, and salts thereof.

US 8,586,749 B2
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(Compound 1 S31-201.1066)

The disclosure also contemplates that the invention
includes the compound of Formula 1 used in a pharmaceutical
composition acceptable for administration to a patient.
Those skilled in the art should recognize that the compounds of this invention may be administered to mammals,
preferably humans, either alone or in combination with pharmaceutically acceptable carriers, excipients or diluents, in a
pharmaceutical composition, according to standard pharmaceutical practice. The compounds can be administered by any
route but are preferably administered parenterally, including
by intravenous, intramuscular, intraperitoneal, subcutaneous,
rectal and also by topical routes of administration.
The term "composition" is intended to encompass a product comprising the disclosed compounds in amounts effective
for causing the desired effect in the patient, as well as any
product which results, directly or indirectly, from combination of the specific ingredients. However, the skilled should
understand that when a composition according to this invention is administered to a human subject, the daily dosage of
active agents will normally be determined by the prescribing
physician with the dosage generally varying according to the
age, weight, sex and response of the individual patient, as well
as the severity of the patient's symptoms.
The terms pharmaceutical composition, pharmaceutically
and/or pharmacologically acceptable for administration to a
patient refer to molecular entities and/or compositions that do
not produce an adverse, allergic and/or other untoward reacti on when administered to a subject, be it animal or human, as
appropriate.
As known to the skilled, a pharmaceutically acceptable
composition or carrier includes any and/or all solvents, dispersion media, coatings, antibacterial and/or antifungal
agents, isotonic and/or absorption delaying agents and/or the
like. The use of such media and/or agents for pharmaceutical
active substances is well known in the art. Except insofar as
any conventional media and/or agent is incompatible with the
active ingredient, its use in the therapeutic compositions is
contemplated. Supplementary active ingredients can also be
incorporated into the compositions. For administration,
preparations should meet sterility, pyrogenicity, general
safety and/or purity standards as required by FDA Office of
Biologics standards.
The skilled will find additional guidance in preparation of
pharmaceutically acceptable compositions by consulting
United States Pharmacopeia (USP) or other similar treatises
employed in the pharmaceutical industry.
The novel compound of Formula 1, given above, may be
used in various methods of treatment, for example: a method
of treatment effective to inhibit a cancer cell by contacting the

20

cell with said compound; a method of treatment effective to
inhibit a human pancreatic cancer cell by contacting the cell
with said compound; a method of treatment effective to
inhibit a human breast cancer cell by contacting the cell with
said compound; a method of treatment effective to inhibit a
cell characterized by an aberrant level of Stat3 by contacting
the cell with said compound; to inhibit a cell characterized by
an aberrant level of Stat3 by contacting the cell with said
compound so as to selectively bind Stat3; to down-regulate
expression ofStat3-regulated genes in a cell by contacting the
cell with said compound; to selectively inhibit Stat3-DNA
binding activity in a cell by contacting the cell with said
compound; to block Stat3 association with epidermal growth
factor receptor in EGF-stimulated fibroblasts by contacting
the fibroblasts with said compound; and to inhibit tumor cells
dependent on aberrant Stat3-mediated oncogenesis by contacting the tumor cells with said compound so as to interfere
with Stat3 function.
The present disclosure also contemplates a second compound, related to the compound of Formula 1 by both being
analogs of S3I-201. This second compound is shown below
according to Formula 2 and salts thereof.

25
Formula 2
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OH

(Compound S31-201.2096)

The compound of Formula 2 has properties that parallel those
of the compound of Formula 1 and may be employed in a
likewise manner, as described above.
As used herein, the terms "treat," "treating" or "method of
treatment" refer to both therapeutic treatment and prophylactic or preventive measures, wherein the object is to prevent or
slow down (lessen) an undesired physiological change or
disorder, such as the development or spread of cancer or other
proliferation disorder. For purposes of this invention, beneficial or desired clinical results include, but are not limited to,
alleviation of symptoms, diminishment of extent of disease,
stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the
disease state, and remission (whether partial or total),
whether detectable or undetectable. For example, treatment
with a compound of the invention may include reduction of
undesirable cell proliferation, and/or induction of apoptosis
and cytotoxicity.
"Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in
need of treatment include those already with the condition or
disorder as well as those prone to have the condition or
disorder or those in which the condition or disorder is to be
prevented or onset delayed. Optionally, the patient may be
identified (e.g., diagnosed) as one suffering from the disease

US 8,586,749 B2
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or condition (e.g., proliferation disorder) prior to administration of the Stat3 inhibitor of the invention.
The terms "effective to inhibit" or "growth inhibitory
amount" of the compounds of the invention refer to an amount
which reduces (i.e., slows to some extent and preferably
stops) proliferation of a target cell, such as a tumor cell, either
in vitro or in vivo, irrespective of the mechanism by which
cell growth is inhibited (e.g., by cytostatic properties, cytotoxic properties, etc.).

plexes in gel are shown, control(-) lane or zero (0) represent
0.05% DMSO. Data are representative of 2-4 independent
determinations;
FIG. 4 shows the effect of S3I-201.1066 on the colocalization or association of Stat3 with EGF receptor and on Stat3
nuclear translocation. (A) Immunofluorescence imaging/
confocal microscopy of Stat3 colocalization with EGFR and
Stat3 nuclear localization in EGF-stimulated (1 g/ml; 10 min)
NIH3T3/hEGFR pre-treated with or without 50 µM
S3I-201.1066 for 30 min; or (B) Immunoblotting analysis of
(i) EGFR immunecomplex (upper panel) or whole-cell
lysates (lower panel) from S3I201.1066-treated Pane-I and
MDA-MB-231 cells, or (ii) immunecomplexes ofEGFR (upper panel) or Stat3 (lower panel) treated with the indicated
concentrations of S3I-201.1066 and probing for EGFR,
Stat3 , She, Grb 2 , or Erkl/2MAPK. Data are representative of
three independent studies;
FIG. 5 indicates that S3I-201.1066 suppresses viability,
growth and survival of malignant cells that harbor persistently-active Stat3 Human breast (MDA-MB-231) and pancreatic (Pane-I) cancer cells, the normal mouse fibroblasts
(NIH3T3) and their v-Src transformed (NIH3T3/v-Src) or
v-Ras transformed (NIH3T3/v-Ras) counterparts, mousethymic epithelial stromal cells (TE-71 ), Stat3 null mouse embryonic fibroblasts (Stat3-/-), and the normal human pancreatic
duct epithelial cells (HPDEC) were treated once or untreated
with 30-100 M S3I-201.1066 for 24-144 h. Cells were (A)
assayed for viability using CyQuant cell proliferation kit;
IC 50 values were derived from graphical representation; (B)
harvested at each 24-h period following treatment and viable
cells counted by trypan blue exclusion with phase-contrast
microscopy; or (C) allowed to culture until large colonies
were visible, which were stained with crystal violet and enumerated. Values are the mean and S.D. of 3-4 independent
determinations. p values, * -<0.05, and ** -<0.01;
FIG. 6 demonstrates that s3 I- 20l.l 06 6 blocks Stat3-dependent malignant transformation and inhibits the migration
of malignant cells harboring aberrant Stat3. (A) Viral Srctransformed mouse fibroblasts (NIH3T3/v-Src) and counterpart transformed by v-Ras (NIH3T3/v-Ras) growing in softagar suspension were treated with or without 30-100 µM
S3I-201.1066 every 2-3 days until large colonies were visible, which were stained with crystal violet and enumerated;
(B) Wound healing assay for effect on cell migration in which
human breast (MDA-MB-231) and pancreatic (Pane-I) cancer cells, and the v-Src transformed mouse fibroblasts
(NIH3T3/v-Src) and counterparts transformed by v-Ras
(NIH3 T3/v-Ras) were treated with or without 30-80 µM S3I201.1066forl2-24handallowedtomigrateintothedenuded
area. Cell migration was visualized at !Ox magnification by
light microscopy and cells that migrated into the denuded area
counted and plotted against the concentration of
S3I-201.1066. Values are the mean and S.D. of3 independent
determinations. p values, * -<0.05, and ** -<0.01.
FIG. 7 shows that S3I-201.1066 suppresses c-Myc, BclxL, MMP-9 and VEGF expression. SDS-PAGE and Western
blotting analysis of whole-cell lysates prepared from the
human breast cancer MDA-MB-231 and pancreatic cancer
Pane-I cells untreated (DMSO, control) or treated with
80-100µMS3I-201.1066for48handprobingwithanti-Myc,
Bcl-xL, MMP-9, VEGF or ~-actin antibodies. Positions of
proteins in gel are shown. Data are representative of 3 independent determinations; and
FIG. 8 shows that S3I-M2001 inhibits growth of human
breast tumor xenografts. Human breast (MDA-MB231)
tumor-bearing mice were given S3I-201.1066 (3 mg kg-1) or
vehicle (0.1 % DMSO in PBS) i.v. every 2 or 3 days. Tumor
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BRIEF DESCRIPTION OF THE DRAWINGS
Some of the features, advantages, and benefits of the
present invention having been stated, others will become
apparent as the description proceeds when taken in conjunction with the accompanying drawings, presented for solely
for exemplary purposes and not with intent to limit the invention thereto, and in which:
FIG. l(A-C), illustrates structures of(A) S3I-201, (B) S3I201.1066 and (C) S3I-201.2096; D and E, GOLD docking of
(D) S3I-201 (green), and (E) S3I-201.1066 (yellow) and S3I201.2096 (green) to the SH2 domain of Stat3; arrow denotes
potential binding sub-pocket;
FIG. 2 shows effects ofS3I-201.1066 and S3I-201.2096 on
the activities of STATs, Src, Jakl, She, and Erks. (A) Nuclear
extracts of equal total protein containing activated Stat!,
Stat3, and/or Stat5 were pre-incubated with or without (i),
(iii) and (iv) S3I-201.1066 or (ii) S3I-201.2096 for 30 min at
room temperature prior to the incubation with the radiolabeled hSIE probe that binds Stat! and Stat3 or the MGFe
probe that binds Stat5 and subjecting to EMSA analysis; (B)
Nuclear extracts of equal total protein prepared from malignant cells following 24-h treatment with or without s3I201.1066 were subjected to in vitro DNA-binding assay using
the radiolabeled hSIE probe and analyzed by EMSA; (C)
Cytosolic extracts of equal total protein were prepared from
36-h S3I-201.1066-treated or untreated NIH3T3/v-Src fibroblasts that stably express the Stat3-dependent luciferase
reporter (pLucTKS3) and analyzed for luciferase activity
using a luminometer; and (D) SDS-PAGE and Western blotting analysis ofwhole-cell lysates of equal total protein prepared from S3I-201.1066-treated oruntreated NIH3T3/v-Src
and Pane-I cells probing for pY705Stat3, Stat3, pY416Src,
Src, pJakl, Jakl, pShc, She, pErkl/2 andErkl/2. Positions of
STATs:DNA complexes or proteins in gel are labeled; control
lanes (0) represent nuclear extracts treated with 0.05%
DMSO, or nuclear extracts or whole-cell lysates prepared
from 0.05% DMSO-treated cells. Data are representative of
3-4 independent determinations. ** -<O .01 ;
FIG. 3 depicts studies of the interaction of S3I-201.1066
with Stat3 or the Stat3 SH2 domain. (A) EMSA analysis ofin
vitro binding of Stat3 to the radiolabeled hSIE probe using
nuclear extracts containing activated Stat3 pre-incubated
with 0-100 µM S3I-201.1066 in the presence or absence of
increasing concentrations of purified His-tagged Stat3 SH2
domain; (B) Surface Plasmon Resonance analysis of the
binding of (i) GYLPQTV-NH2 (unphosphorylated, high
affinity gp-130 peptide), (ii) GpYLTQTV-NH2 (phosphorylated), or (iii) small-molecule S3I-201.1066 as analyte to the
purified His-tagged Stat3 immobilized on HisCap Sensor
Chip; and (C) Fluorescence Polarization assay of the binding
to the 5carboxyfluorescein-GpYLPQTV-NH2 probe of (i)
increasing concentration of purified His-Stat3 or (ii) a fixed
amount of purified His-Stat3 (150 nM) in the presence of
increasing concentrations of S3I201.1066. Stat3:DNA com-
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sizes, measured every 2 or 3 days, were converted to tumor
volumes and plotted against treatment days; Values are the
mean and S.D. from replicates of 12 tumor-bearing mice in
each group. *<0.05.

Cloning and Protein Expression
Coding regions for the murine Stat3 protein and Stat3 SH2
domain were amplified by PCR and cloned into vectors pET44 Ek/LIC (Novagen) and pET SUMO (Invitrogen), respectively.
The primers used for amplification were: Stat3 Forward:
GACGACGACAAGATGGCTCAGTGGAACCAGCTGC
(SEQ ID NO:l); Stat3 Reverse: GAGGAGAAGCCCGGTTATCACATGGGGGAGGTAGCACACT (SEQ ID N0:2);
Stat3-SH2 Forward: ATGGGTTTCATCAGCAAGGA (SEQ
ID N0:3); Stat3-SH2 Reverse: TCACCTACAGTACTTTCCAAATGC (SEQ ID N0:4).
Clones were sequenced to verify the correct sequences and
orientation. His-tagged recombinant proteins were expressed
in BL21(DE3) cells, and purified on Ni-ion sepharose colunm.
Nuclear Extract Preparation, Gel Shift Assays, and Densitometric Analysis
Nuclear extract preparations and electrophoretic mobility
shift assay (EMSA) were carried out as previously described
(28,33). The 32 P-labeled oligonucleotide probes used were
hSIE (high affinity sis-inducible element from the c-fos gene,
m67 variant, 5'AGCTTCATTTCCCGTAAATCCCTA; SEQ
ID N0:5) that binds Stat! and Stat3 (34) and MGFe (mammary gland factor element from the bovine ~-casein gene
promoter, 5'-AGATTTCTAGGAATTCAA; SEQ ID N0:6)
for Stat! and Stat5 binding (35,36). Except where indicated,
nuclear extracts were pre-incubated with compound for 30
min at room temperature prior to incubation with the radiolabeled probe for 30 min at 30° C. before subjecting to EMSA
analysis. Bands corresponding to DNA-binding activities
were scanned and quantified for each concentration of compound using ImageQuant and plotted as percent of control
(vehicle) against concentration of compound, from which the
IC 50 values were derived, as previously reported (37).
Immunoprecipitation and SDS-PAGE/Western Blotting
Analysis
Immunoprecipitation from whole-cell lysates and SDS/
PAGE and Western blotting analysis were performed as previously described (33,38). Primary antibodies used were antiStat3, pY705Stat3, pY416Src, Src, pErkl/2, Erkl/2, pJakl,
Jakl, pShc, She, Grb 2, c-Myc, Bcl-xL, MMP-9, and ~-Actin
(Cell Signaling, Danvers), and VEGF (Santa Cruz Biotech,
Santa Cruz).
Cell Viability and Proliferation Assay
Cells in culture in 6-well or 96-well plates were treated
with or without
S3I-201.1066 for 24-144 hand subjected to CyQuant cell
proliferation assay (Invitrogen Corp/Life Technologies Corp,
Carlsbad, Calif.), or harvested, and the viable cells counted by
trypan blue exclusion with phase contrast microscopy.
Immunofluorescence Imaging/Confocal Microscopy
NIH3T3/hEGFR cells were grown in multi-cell plates,
serum-starved for 8 h and treated with or without
S3I-201.1066 for 30 min prior to stimulation by rhEGF (1
g/ml) for 10 min. Cells were fixed with ice-cold methanol for
15 min, washed 3 times in PBS, permeabilized with 0.2%
Triton® X-100 for 10 min, and further washed 3-4 times with
PBS. Specimens were then blocked in 1% BSA for 30 min
and incubated with EGFR (Santa Cruz) or Stat3 (Cell Signaling Tech) antibody at 1:50 dilution at 4° C. overnight. Subsequently, cells were rinsed 4-5 times in PBS, incubated with
Alexafluor 546 rat antibody for EGFR detection and Alexa
fluor 488 rabbit antibody for Stat3 detection (Invitrogen) for
1 h at room temperature in the dark. Specimens were then
washed 5 times with PBS, covered with cover slides with
VECTASHIELD mounting medium containing DAPI, and
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DETAILED DESCRIPTION OF PREFERRED
EMBODIMENTS
The present invention will now be described more fully
hereinafter with reference to the accompanying drawings, in
which preferred embodiments of the invention are shown.
Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which this invention
pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or
testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, or other references mentioned or cited herein
are incorporated by reference in their entirety. In case of
conflict, the present specification, including any definitions,
will control. In addition, those of skill in the art should recognize that the materials, methods and examples given are
illustrative in nature only and not intended to be limiting.
Accordingly, this invention may be embodied in many different forms and should not be construed as limited to the illustrated embodiments set forth herein. Rather, the illustrated
embodiments are provided so that this disclosure will be
thorough and complete, and will fully convey the scope of the
invention to those skilled in the art. Other features and advantages of the invention will be apparent from the following
detailed description, and from the claims.
The abbreviations used herein are: STAT, signal transducer
and activator of transcription; PBST, phosphate-buffered
saline Tween-20®; HPDEC, normal human pancreatic duct
epithelial cell line; Stat3-/-, Stat3 knockout mouse embryonic fibroblasts; PBS, phosphate-buffered saline;
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EMSA, electrophoretic mobility shift assay; Erk, extracellular signal-regulated kinase; FBS, fetal bovine serum,
MMP-9, matrix metalloproteinases 9.
Experimental Procedures
Cells and Reagents
Normal mouse fibroblasts (NIH3T3) and counterparts
transformed by v-Src (NIH3T3/v-Src), v-Ras (NIH3T3/vRas) or overexpressing the human epidermal growth factor
(EGF) receptor (NIH3T3/hEGFR), and the human breast
cancer (MDA-MB-231) and pancreatic cancer (Pane-I) cells
have all been previously reported (15, 27-29). The normal
human pancreatic duct epithelial cells (HPDEC) was a kind
gift from Dr. Tsao, (OCI, UHN-PMH, Toronto) (30), Stat3
knockout mouse embryonic fibroblasts was generously provided by Dr. Poli (31 ), and the mouse thymic epithelial stromal cells (TE-71) was a generous gift from Dr. Farr (32). The
Stat3dependent reporter, pLucTKS3 and the v-Src transformedmouse fibroblasts that stably express pLucTKS3 have
been previously reported (15, 33). Cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10%
heat-inactivated fetal bovine serum, or in the case ofHPDEC,
they were grown in Keratinocyte-SFM media supplemented
with 0.2 ng EGF, 30 µg/ml bovine pituitary extract and containing antimycol. Antibodies against Stat3, pY705Stat3,
Src, pY416Src, Jakl, pJakl, She, pShc, Erkl/2, and pErkl/2
are from Cell Signaling Technology (Danvers, Mass.).
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examined innnediately under a Leica TCS SP5 confocal
microscope (Germany) at appropriate wavelengths. Images
were captured and processed using the Leica TCS SP 5 software.
Soft-Agar Colony Formation Assay
Colony formation assays were carried out in 6-well dishes,
as described previously (16,3 7). Briefly, each well contained
1.5 ml of 1% agarose in Dulbeco's modified Eagle's medium
as the bottom layer and 1.5 ml of0.5% agarose in Dulbeco's
modified Eagle's medium containing 4000 or 6000 NIH3T3/
v-Src or NIH3T3/v-Ras fibroblasts, respectively, as the top
layer. Treatment with S3I201.1066 was initiated 1 day after
seeding cells by adding 80 µl of medium with or without
S31201.1066, and repeating every 3 days, until large colonies
were evident. Colonies were quantified by staining with 20p1
of 1 mg/ml crystal violet, incubating at 3 7° C. overnight, and
counting the next day under phase contrast microscope.
Fluorescence Polarization Assay
Fluorescence Polarization (FP) Assay was conducted as
previously reported (23), with some modification using the
phospho-peptide, 5-carboxyfluoresceinGpYLPQTV-NH2
(where pY represents phospho-Tyr) as probe and Stat3. The
FP assay was used to evaluate the binding of agents to Stat3
and to determine the ability to disrupt the Stat3:pTyr peptide
interaction.A fixed concentration of the fluorescently-labeled
peptide probe (10 nM) was incubated with increasing concentration of the Stat3 protein for 30 min at room temperature
in the buffer, 50 mM NaCl, 10 mM HEPES, 1 mM EDTA,
0.1 % Nonidet P-40, and the fluorescentpolarizationmeasurements were determined using the POLARstar Omega (BMG
LABTECH, Durham, N.C.), with the set gain adjustment at
35 mP. The Z' value was derived per the equation Z'=l(3SD60und+3SDfree)l(mP60unamPfree), where SD is the standard deviation and mP is the average of fluorescence polarization. In the bound state, 10 nM 5-carboxyfluoresceinGp YLPQTV-NH2 was incubated with 150 nM purified Stat3
protein, while the free (unbound) state was the same mixture,
but incubated with an additional 10 µM unlabeled
Ac-GpYLPQTV-NH 2 . For evaluating agents, Stat3 protein
(150 nM) was incubated with serial concentrations of S3I201.1066 at 30° C. for 60 min in the indicated assay buffer
conditions. Prior to the addition of the fluorescence pro be, the
protein:S3I-201.1066 mixtures were allowed to equilibrate at
room temperature for 15 min. Probe was added at a final
concentration of 10 nM and incubated for 30 min at room
temperature following which the FP measurements were
taken using the POLARstar Omega, with the set gain adjustment at 35 mP.
Surface Plasmon Resonance Analysis
SensiQ and its analysis software Qdat (ICX Technologies,
Oklahoma City, Okla.) were used to analyze the interaction
between agents and the Stat3 protein and to determine the
binding affinity. Purified Stat3 was innnobilized on a HisCap
Sensor Chip by injecting 50 g/ml of Stat3 onto the chip.
Various concentrations ofS3I-201.1066 in running buffer (1 x
PBS, 0.5% DMSO) were passed over the sensor chip to
produce response signals. The association and dissociation
rate constants were calculated using the Qdat software. The
ratio of the association and dissociation rate constants was
determined as the affinity (Kn)·
Colony Survival Assay
This was performed as previously reported (39). Briefly,
cells were seeded as single-cell in 6-cm dishes (500 cells per
well), treated once the next day with S3I-201.1066 for 48 h,
and allowed to grow until large colonies were visible. Colonies were stained with crystal violet for 4 hand counted under
phase-contrast microscope.

Wound Healing Assay for Migration
Wounds were made using pipette tips in monolayer cultures of cells in six-well plates. Cells were treated with or
without increasing concentrations of S3I-201.1066 and
allowed to migrate into the denuded area for 12-24 hours. The
migration of cells was visualized at a 1Ox magnification using
an Axiovert 200 Inverted Fluorescence Microscope (Zeiss,
Giittingen Germany), with pictures taken using a mounted
Canon Powershot A640 digital camera (Canon USA, Lake
Success, N.Y.). Cells that migrated into the denuded area
were quantified. Mice and in vivo tumor studies-Six-weekold female athymic nude mice were purchased from Harlan
and maintained in the institutional animal facilities approved
by the American Association for Accreditation of Laboratory
Animal Care. Athymic nude mice were injected subcutaneously in the left flank area with 5xl0 6 human breast cancer
MDA-MB-231 cells in 100 µL of PBS. After 5 to 10 days,
tumors of a diameter of3 mm were established. Animals were
grouped so that the mean tumor sizes in all groups were nearly
identical, then given S3I-201.1066 intravenously at 3 mg/kg
every 2 or every 3 days for 17 days and monitored every 2 or
3 days, and tumor sizes were measured with calipers. Tumor
volume was calculated according to the formula V=0.52xa 2 x
b, where a, smallest superficial diameter, b, largest superficial
diameter.
Statistical Analysis
Statistical analysis was performed on mean values using
Prism GraphPad Software, Inc. (La Jolla, Calif.). The significance of differences between groups was determined by the
paired t-test at p<0.05*, <0.01 **,and <0.001 ***.
Results
Computer-Aided Design of S3I-201 Analogs as Stat3 Inhibitors.
Close structural analysis of the lowest Genetic Optimization for Ligand Docking (GOLD) (40) conformation of the
lead Stat3 inhibitor, S3I-201 (yellow) (IC 50 =86 µM for inhibition of Stat3:Stat3 (18)) (FIG. lA) bound within the Stat3
SH2 domain (FIG. lD), per the X-ray crystal structure of
DNA-bound Stat3~ homodimer (26) showed significant
complementary interactions between the protein surface and
the compound and identified key structural requirements for
tight binding. Docking studies permitted in silica structural
design of analogs of differing Stat3 SH2 domain-binding
characteristics in order to derive Stat3 inhibitors of improved
potency and selectivity. GOLD docking studies showed limited structural occupation of the Stat3-SH2 domain, identifying a potential means for improving inhibitor potency. The
SH2 domain is broadly composed of three sub-pockets, only
two of which are accessed by S3I-201 (FIG. lD). Lead agent,
S3I-201 (FIG. lA) has a glycolic acid scaffold with its carboxylic acid condensed with a hetero-trisubstituted aromatic
species to furnish the amide bond, and a hydroxyl moiety that
has been tosylated. The ortho-hydroxybenzoic acid component is a known pTyr mimetic, and low energy GOLD docking studies consistently placed this unit in the pTyr-binding
site, making hydrogen bonds and electrostatic interactions
withLys591, Ser611, Ser613 andArg609. Due to the strength
of such interactions between oppositely charged ions, it is
likely that a considerable portion of the binding between the
SH2 domain and S3I-201 arises from the pTyr mimetic. The
Otosyl group binds in the mostly-hydrophobic pocket that is
derived from the tetramethylene portion of the side chain of
Lys592 and the trimethylene portion of the side chain of
Arg595, along with Ile597 and Ile634. Given the potency of
S3I-201 towards Stat3 inhibition, a rational synthetic program was undertaken to modify and optimize the core scaffold to furnish more potent analogs. We additionally
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exploited key hydrophobic interactions with Phe716, 11 e659,
Val637 and Trp623 (FIG. lD) ingenerating compounds made
ofN-substituted (paracyclohexyl)benzyl analogs (FIGS. 1B
andC).
A paper by Fletcher et al. entitled, Disruption ofTranscriptionally Active Stat3 Dimers with Non-Phosphorylated, Salicylic Acid-Based Small Molecules: Potent In vitro and Tumor
Cell Activities, which reports on the details of the design and
synthesis of the series ofS3I-201 analogs may be used by the
skilled for guidance in synthesizing the novel compounds
disclosed herein (41).
Inhibition of Stat3 DNA-Binding Activity.
S3I201 analogs derived per in silica structural optimization and molecular modeling of the binding to the Stat3 SH2
domain were synthesized and evaluated in Stat3 DNA-binding assay in vitro, as previously done (18). Nuclear extracts
containing activated Stat3 prepared from v-Src transformed
mouse fibroblasts (NIH3T3/v-Src) that harbor aberrant Stat3
were incubated for 30 min at room temperature with or without increasing concentrations of the analogs, S3I201.1066
and S3I-201.2096, prior to incubation with the radiolabeled
hSIE probe that binds to Stat3 and Stat! and subjecting to
electrophoretic mobility shift assay (EMSA) analysis (18).
Stat3 DNA-binding activity was inhibited in a dose-dependent manner by both S3I-201.1066 and S3I201.2096 (FIGS.
2A(i) and (ii)), with average IC 50 values of 35±09 µMand
45±12 µM, respectively. These values represent 2-3 fold
improvement over the activity of the lead agent, S3I-201
(IC 50 of 86 µM) (18), from which the present compounds
were derived. For selectivity, nuclear extracts containing activated Stat!, Stat3 and Stat5 prepared from EGF-stimulated
NIH3T3/hEGFR (mouse fibroblasts over-expressing the
human epidermal growth factor receptor, EGFR) were preincubated at room temperature with or without increasing
concentrations of S3I-201.1066 for 30 min, prior to incubation with the radiolabeled oligonucleotide probes and subjecting to EMSA analyses, as previously done (18). EMSA
results of the binding studies using the hSIE probe shows the
strongest complex ofStat3:Stat3 with the probe (upper band,
lanes I and 2), which is significantly disrupted at 50 µM
S3I-201.1066 and completely disrupted at 100 µM
S3I-201.1066 (FIG. 2A(iii), upper band, lanes 2 and 3).
EMSA analysis further shows a less intense Stat! :Stat3 complex (intermediate band), which is similarly repressed at 50
µMand completely disrupted at 100 µM S3I-201.1066 (FIG.
2A(iii), lanes 2 and 3 ). By contrast, we observe no significant
inhibition of the Statl:Statl complex that is of the lowest
intensity (lower band) at 50 µM S3I-201.1066, a moderate
inhibition at 100 µM S3I-201.1066, while a complete inhibition occurred at 200 µM S3I-201.1066 (FIG. 2A(iii), lower
band). Of importance, at the 100 µM S3I-201.1066 concentration at which only a moderate inhibition of Stat! :Stat!
complex occurred, the larger Stat3:Stat3 complex is completely dissociated (FIG. 2A, lane 3). Moreover, EMSA
analysis showed no effect on Stat5:Stat5 complex with the
MGFe probe, up to 300 µM S3I-201.1066 (FIG. 2A(iv)).
Thus, S3I-201.1066 preferentially inhibits DNA-binding
activity of Stat3 over that of Stat! and Stat5.
Inhibition of Intracellular Stat3 Activation.
Stat3 is constitutively activated in a variety of malignant
cells, including human breast and pancreatic cancer cells
(9,10,20). Given the effect against Stat3 DNA-binding activity in vitro, we evaluated S3I-201.1066 in v-Src transformed
mouse fibroblasts (NIH3T3/v-Src), human breast cancer
(MDA-MB-231) and human pancreatic cancer (Pane-I) lines
that harbor aberrant Stat3 activity.

Twenty-four hours after treatment, nuclear extracts were
prepared from cells and subjected to Stat3 DNA-binding
assay in vitro using the radio labeled hSIE probe and analyzed
by EMSA. Compared to the control (0.05% DMSO-treated
cells, lane I), nuclear extracts from S3I-201.1066-treated
NIH3T3/v-Src, Pane-I and MDA-MB-231 cells showed
dose-dependent decreases of constitutive Stat3 activation,
with significant inhibition at 50 µM S3I-201.1066 (FIG. 2B,
compare lanes 2-5, 810, and 13-15 to their respective controls
(0)). Luciferase reporter studies were performed to further
determine the effect of S3I-201. I 066 on Stat3 transcriptional
activity.
Results show that treatment with S3 I-20 I . I 066 of the v-Src
transformed mouse fibroblasts (NIH3T3/v-Src) that stably
express the Stat3-dependent luciferase reporter (pLucTKS3)
(33) significantly (p<0.01) repressed the induction of the
Stat3-dependent reporter (FIG. 2C). SDS-PAGE and Western
blot analysis further showed that treatment with S3I201. I 066
for 24 h induced a concentration-dependent reduction of
pTyr705Stat3 levels in NIH3T3/v-Src (FIG. 2C(i), top panel)
and Pane-I cells (FIG. 2C(ii), top panel), presumably through
the blockade of Stat3 binding to pTyr motifs of receptors and
the prevention of de nova phosphorylation by tyrosine
kinases.
By contrast, immunoblotting analysis of whole-cell lysates
from the two cell line models showed no significant effects of
S3I-201.1066 on the phosphorylation of Src (pY416Src),
Jakl (pJak), She (pShc ), and Erkl/2 (pErkl/2) under the same
treatment conditions, (FIGS. 2C (i) and (ii), panels 2-5 from
the top), except the disappearance of pJakl level in Pane- I
cells at 100 µM S3I201.1066. Total Stat3, Src, Jakl, She and
Erkl/2 protein levels remained unchanged. We infer that at
the concentrations that inhibit Stat3 activity, S3I-201.1066
has minimal effect on Src, Jakl, She and Erkl/2 activation.
In Vitro Evidence that S3I-201.1066 Interacts with Stat3 (or
SH2 Domain) and Selectively Disrupts Stat3 Binding to Cognate pTyr Peptide Motif of Receptor.
Given the computational modeling prediction that S3I201.1066 interacts with the Stat3 SH2 domain, we deduce
that S3I201.I 066 blocks Stat3 DNA-binding activity by binding to the Stat3 SH2 domain, thereby disrupting Stat3:Stat3
dimerization. To determine therefore ifthe Stat3 SH2 domain
could interact with S3I-201.1066, we tested whether the addition of the recombinant Stat3 SH2 domain into the DNAbinding assay mixture could intercept the inhibitory effect of
the agent on Stat3 activity that is observed in FIG. 2A(i).
Purified histidine-tagged Stat3 SH2 domain (His-SH2) was
added at increasing concentrations (1-500 ng) to nuclear
extracts containing activated Stat3 and the mixed extracts
were subjected to DNA-binding assay in vitro forthe study of
the effect ofS3I-201.1066, as was done in FIG. 2A(i). EMSA
analysis shows a strong inhibition by S3I-201.1066 ofStat3
DNA-binding activity, as shown in FIG. 2A(i), when no HisSH2 domain was added to the nuclear extracts (FIG. 3A, lanes
2, 7, and 9 compared to lane I). By contrast, the observed
S3I-201.0166-mediated inhibition of Stat3 DNA-binding
activity was progressively eliminated by the presence of an
increasing concentration of purified His-SH2 domain (Stat3
SH2), leading to the full recovery of Stat3 activity when
recombinant SH2 domain protein was present at 125-500 ng
(FIG. 3A, lanes 3-6, 8 and 10).
The preceding studies suggest that S3I-201.1066 interacts
with the Stat3 SH2 domain. However, the studies do not
demonstrate a direct binding to the Stat3 SH2 domain. To
provide definitive evidence of direct binding to Stat3, biophysical studies were performed. His-tagged Stat3 protein (or
SH2 domain; 50 ng) was immobilized on a Ni-NTA sensor
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chip surface for Surface Plasmon Resonance analysis of the
binding of S3I201.1066 as the analyte. Association and dissociation measurements were taken and the binding affinity
of S3I-201.1066 for Stat3 was determined using Qdat software. Results showed a gradual increase and decrease with
time in the signals (response unit (RU)) for the association
and dissociation, respectively, of the agent upon its addition
to the immobilized His-Stat3 (FIG. 3B(iii)), indicative of the
binding of S3I-201.1066 to and dissociation from the Stat3
protein. The curves depicted interactions between Stat3 and
S3I-201.1066, with a binding affinity, Knof2.74nM/providing the first definitive evidence of direct Stat3 binding for
S3I-201 or its derivatives. The interactions also showed a
dependency on the concentration of the S3I-201.1066 (FIG.
3B(iii)). This SPR analysis of the conformational changes in
His-Stat3 was validated by using the high affinity Stat3-binding phosphoTyr (pY) peptide, GpYLPQTV-NH2 derived
from the interleukin-6 receptor (IL-6R) subunit, gp-130 (22,
23) (with a Kn of24 nM) (FIG. 3B(ii)), and its non-phosphorylated counterpart, GYLPQTV-NH 2 , which showed little
evidence of significant binding to Stat3 (FIG. 3B(i)). Interestingly, the dissociation curve for S3I-201.1066 showed a
large residual binding to Stat3 between 500-1000 s (FIG.
3B(iii), 10-50 µM, 500-1000 s), compared to the rapid association and dissociation of the high affinity peptide to and
from Stat3 with no residual binding of the phosphopeptide
(FIG. 3B(ii)). The implication of this finding is presently
unknown, but may suggest a slower "off' rate for the dissociation ofS3I-201.1066 from Stat3. Differences in the chemical compositions and physicochemical properties would
account for these different behaviors of interactions with the
Stat3 protein.
The studies so far demonstrate that S3I201.1066 interacts
with Stat3 or the Stat3 SH2 domain (data not shown). The
interaction with the Stat3 SH2 domain could block the binding ofStat3 to its cognate pTyrpeptide motifs of receptors. To
verify that the agent disrupts pTyr-Stat3 SH2 domain interactions, hence Stat3:Stat3 dimerization, we set up a fluorescence polarization (FP) study based on the binding of Stat3 to
the high affinity peptide, GpYLPQTV-NH2 (22,23). It has
previously been reported that Stat3 binds to Gp YLPQTVNH2 with a higher affinity than to the Stat3-derived pTyr
peptide, Pp YLKTK. This high affinity peptide disrupted
Stat3 DNA-binding activity in vitro withanIC 50 value of0.15
µM (22). The FP assay utilizing the 5carboxyfluoresceinGp YLPQTV-NH2 as a probe showed a saturation curve in the
fluorescence polarization signal (mP) with increasing concentration (in µM) of purified His-Stat3 for a robust Z' value
of 0.84 (FIG. 3C(i)), which closely matches the previously
reported value of0.87 (23).
Test of the non-phosphorylated, non-labeled GYLPQTVNH2 in the FP assay showed no evidence of effect on the
fluorescent polarization signal (data not shown), while as
expected, the phosphorylated, unlabeled counterpart,
GpYLPQTV-NH2 induced a complete inhibition with an
IC 50 value of 0.3 µM (data not shown), consistent with the
previously reported value of 0.25±0.03 µM (23). The FP
assay was used to further test the computational modeling
prediction of the ability of S3I-201.1066 to disrupt Stat3
interaction with its cognate pTyr peptide. Results show that
S3I-201.1066, in a concentration-dependent manner, abrogated the fluorescent polarization signal for the interaction
between the fluorescently-labeled phosphopeptide and Stat3
(FIG. 3C(ii)). The inhibitory constant (IC 50 value) was
derived to be 20±7.3 µM, which is within the range for the
IC 50 value (35±9 µM) determined for the inhibition of Stat3
DNA-binding activity (FIG. 2A(i)). These findings together

indicate that S3I-201.1066 binds to Stat3 or its SH2 domain
and disrupts the interaction of Stat3 with its pTyr peptide,
thereby blocking Stat3 DNA-binding activity.
To further verify that S3I-201.1066 disrupts the binding of
Stat3 to receptors, mouse fibroblasts over-expressing the
EGF receptor (NIH3 T3/hEGFR) were treated with or without
the compound prior to stimulation with EGF for 10 min. Cells
were then subjected to immunostaining for EGFR (red) and
Stat3 (green) and analyzed by confocal microscopy for EGFinduced colocalization of Stat3 and EGFR and for Stat3
nuclear translocation, as previously performed (17). In the
resting NIH3T3/hEGFR fibroblasts, EGFR (red) is widely
localized at the plasma membrane, while Stat3 (green) is
localized at both the plasma membrane and in the cytoplasm,
with a minimal co localization with EGFR at the plasma membrane and no visible presence in the nucleus (stained blue for
DAPI) (FIG. 4A upper panel). Stimulation by EGF of cells
untreated with S3I-201.1066 induced a strong nuclear presence of Stat3 (cyan for merged Stat3 (green) and DAPI
(blue)), as well as co localizations ofEGFR and Stat3 (yellow
for merged EGFR (red) and Stat3 (green)) at the plasma
membrane, cytoplasm, and peri-nuclear space (FIG. 4A, bottom left). This EGF-stimulated colocalization between
EGFR and Stat3 and the Stat3 nuclear localization were both
strongly blocked when cells were pre-treated with
S3I-201.1066 before stimulating with EGF (FIG. 4A, bottom
right compared to non-treated, bottom left), indicating that
the compound disrupts Stat3 binding to EGFR. We infer that
by blocking Stat3 binding to EGFR, S3I-201.1066 attenuates
Stat3 phosphorylation/activation and thereby prevents Stat3
nucleartranslocation. To investigate furtherthe Stat3 interaction with the EGFR receptor and the effect ofS3I-201.1066,
coimmunoprecipitation with immunoblotting studies were
performed in which EGFR immunecomplex was immunoprecipitated from whole-cell lysates prepared from treated
and untreated cancer cells and blotted for Stat3, and for She
and Grb 2 as negative control. Results showed that EGFR
immunecomplex precipitated from untreated Panel and
MDA-MB-231 cells contained Stat3, She and Grb 2 (FIG.
4B(i), lanes 1 and3, i.p. EGFR, blotStat3, She, andGrb2). By
contrast, treatment of both cell lines with S3I-201.1066 significantly diminished the level of Stat3 that associated with
EGFR in the immunecomplex of equal total protein without
affecting the She or Grb 2 levels that are associated with
EGFR in the complex. See FIG. 4B(i), lanes 2 and 4, i.p.
EGFR, blot Stat3, She and Grb 2. Western blotting ofwholecell lysates of equal total protein shows the levels of activated
and total Erkl/2 are unaffected by the treatment of cells with
S3I-201.1066 (FIG. 4B(i), input, blot pErk and Erk) and the
Stat3 protein levels remain the same (FIG. 4B(i), input, blot
Stat3).
In other studies, EGFR and Stat3 immunecomplexes were
independently precipitated from whole-cell lysates of
untreated Pane- I cells and complexes of equal total protein
were directly treated with 0-100 M S3I-201.1066 for 3 hand
then subjected to Western blotting analysis. Compared to
untreated samples (FIG. 4B(ii), lane 1), results show that the
direct treatment with S3I-201.1066 of the EGFR immunecomplex dramatically diminished the level ofStat3 present
in the complex (FIG. 4B(ii), i.p. EGFR, blot Stat3, lanes 2-4),
with no visible changes in the levels of She or Grb 2 present
in the complex (FIG. 4B(ii), i.p., EGFR, blot She or Grb 2).
The EGFR levels in the immunecomplexes remained
unchanged (FIG. 4B(ii), upper band). Similarly, the Stat3
immunecomplex that is directly treated with S3I-201.1066
and blotted for EGFR showed strongly reduced EGFR levels,
compared to the untreated Stat3 immunecomplex of equal
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total protein (FIG. 4B(ii), i.p. Stat3, blot EGFR, compare lane
I to lanes 2-4). The Stat3 levels in the immunecomplexes
remained unchanged(FIG. 4B(ii), i.p. Stat3, blot Stat3).Altogether, these findings strongly indicate that S3I-201.1066
disrupts the binding of Stat3 to cognate receptor motifs,
thereby blocking Stat3 phosphorylation and nuclear translocation.
S3I-201.1066 Blocks Growth, Viability, Malignant Transformation, and the Migration of Cells Harboring ConstitutivelyActive Stat3.
Aberrant Stat3 promotes malignant cell proliferation, survival and malignant transformation (10,20,42). Given that
S3I201. I 066 disrupts Stat3 activation, we asked the question
whether this agent is able to selectively decrease the viability
and growth of malignant cells that harbor aberrant Stat3 activity. The human breast (MDA-MB-231) and pancreatic cancer
(Pane-I) lines and the v-Src-transformed mouse fibroblasts
(NIH3T3/v-Src) that harbor constitutively-active Stat3, as
well as cells that do not harbor aberrant Stat3 (normal mouse
fibroblasts (NIH3T3), v-Ras-transformed counterpart fibroblasts (NIH3T3/v-Ras), Stat3 knockout mouse embryonic
fibroblasts (MEFs) (Stat3-/-) (31 ), normal human pancreatic
duct epithelial cells (HPDEC) (30), and mouse thymic epithelial stromal cells (TE-71) cells (3 2)) in culture were treated
with or without an increasing concentration of S3I-201. I 066
for up to 6 days and analyzed for viable cell numbers by
CyQuant cell proliferation/viability kit (FIG. SA) and by
trypan blue exclusion with phase-contrast microscopy (FIG.
SB), as described in the "Materials and Methods".
Compared to the control (DMSO-treated) cells, the mouse
fibroblasts transformed by v-Src (NIH3T3/v-Src), and the
MDA-MB-231 and Pane-I cells showed significantly
reduced viable cell numbers (FIG. SA) and were growth
inhibited (FIG. SB(ii)-(iv)) following treatment with increasing concentrations ofS3I-201. I 066 for 24-144 h. By contrast,
the viability (FIG. SA) and growth (FIG. SB(i) and (v)) of
NIH3T3, Stat3-null MEFs (Stat3-/-), normal human pancreatic duct epithelial cells (HPDEC), and the mouse thymus
epithelial stromal cells (TE71) that do harbor aberrant Stat3
activity were not significantly altered by up to 200 µM
S3I201.1066 treatment (FIG. SA and B, and data not shown),
with derived IC 50 values that are >200 µM, compared to 35,
48, and 37 µM for NIH3T3/v-Src, Pane-I, and MDA-MB231, respectively (FIG. SA, lower panel). These findings suggest that S3I-201.1066 exerts preferential biological effects
against malignant cells that harbor constitutively-active
Stat3, and at concentrations that inhibit Stat3 activity, the
agent does not affect other cells.
We extended these studies to examine the effect of S3I201.1066 in colony survival assay performed as previously
reported (39). Cultured single-cells were untreated or treated
once with S3I-201.1066 and allowed to grow until large colonies were visible, which were stained and enumerated.
Results showed a dose-dependent suppression of the number of colonies for the v-Src transformed mouse fibroblasts
(NIH3T3/v-Src), the human pancreatic cancer, Pane-I and
the human breast cancer, MDA-MB-231 cells (FIG. SC(ii)(iv)). By contrast, minimal effect was observed on the colony
numbers for mouse fibroblasts transformed by v-Ras
(NIH3T3/v-Ras) that do not harbor constitutively-active
Stat3 (FIG. SC(i)). Furthermore, growth in soft-agar suspension of NIH3T3/v-Src, MDA-MB-231 and Pane-I cells
treated with S3I-201.1066 was significantly inhibited (FIG.
6A(ii)-(iv)). By comparison, at concentrations that inhibit
Stat3, S3I-201.1066 showed minimal effect on the soft-agar
growth ofv-Ras transformed mouse fibroblasts (NIH3T3/vRas) (FIG. 6A(i)). These findings indicate that S3I-201.1066

selectively suppresses viability, growth, and survival of
malignant cells harboring aberrant Stat3, and blocks Stat3mediated malignant transformation. Thus, these studies demonstrate that Stat3 is important not only for tumor growth, but
also tumor progression (43,44).
To further investigate the biological effects of
S3I-201.1066 and to assess the ability to block Stat3-dependent tumor progression processes, a wound healing study was
performed, as described in "Materials and Methods" section
for monitoring the migration of malignant cells and the effect
of treatment with S3I-201.1066. Significantly reduced numbers of MDA-MB-231, Pane-I and NIH3T3/v-Src cells
migrating into the denuded area were observed following
12-24 h treatment with S3I-201.1066 (FIG. 6B and data not
shown), with strongly reduced numbers occurring at 50 or
I 00 µM S3I201.I 066 treatment, and statistically lower numbers at 30 M S3I-201.1066 (FIG. 6B). By contrast, the migration ofNIH3T3/v-Ras fibroblasts was minimally affected by
the same treatment conditions (FIG. 6B). In the 12-24 h
treatment duration, there was no evidence of apoptosis of the
treated cells (data not shown). These findings demonstrate
that S3I-201.1066 selectively suppresses the migration of
malignant cells that harbor aberrant Stat3.
S3I-201.1066 Represses the Expression of c-Myc, Bcl-xL,
VEGF, and MMP-9.
Known Stat3 downstream target genes are key in the dysregulated biological processes promoted by aberrant Stat3
(9,20,42). We sought to validate the inhibitory effect of S3I201.I 066 on aberrant Stat3 signaling and to define the underlying molecular mechanisms for the antitumor cell effects of
the agent by investigating changes in the induction of known
Stat3-regulated genes. In the human breast carcinoma, MDAMB-231 and pancreatic cancer, Pane-I cell lines that harbor
constitutively-active Stat3, immunoblotting analysis of
whole-cell lysates shows the constitutive induction of known
Stat3-regulated genes, including c-Myc, Bcl-xL, VEGF, and
MMP-9 proteins, which were significantly suppressed in
response to 48 h-treatment with S3I-201.1066 (FIG. 7 and
data not shown). These data indicate that S3I-201.1066 sufficiently represses the constitutive induction of Stat3-regulated genes, thereby thwarting the effect of aberrant Stat3 in
terms of eliminating the dysregulation of growth and survival
that supports the malignant phenotype. The ability of S3I201.I 066 to block Stat3 transcriptional activity is also supported by the data in FIG. 2C.
S3I-201.1066 Inhibits Growth of Human Breast Tumor
Xenografts.
Given Stat3 's importance in tumor growth and tumor progression, we evaluated S3I-201.1066 in xenograft models of
the human breast cancer (MDA-MB-231) cells that harbor
aberrant Stat3. Compared to control (vehicle-treated), tumorbearing mice, treated (i.v. injection) with S3I-201.1066 at 3
mg/kg every 2 or 3 days for I 7 days had greatly reduced tumor
sizes (FIG. 8). Animals remained viable at this dose and
showed no obvious sign of toxicity. These findings together
demonstrate that S3I-201. I 066 induces antitumor cell effects
and tumor regression by targeting the Stat3 SH2 domain and
thereby inhibiting Stat3-mediated tumor processes.
Discussion
Computational modeling of the interactions of the Stat3
SH2 domain with the previously reported Stat3 inhibitor lead,
S3I-201 (18) derived key structural information for optimization and a rational synthetic program that furnished exciting new analogs. The compounds disclosed herein,
S3I-201.1066 (Formula I) and S3I-201.2096 (Formula 2)
show improved Stat3-inhibitory inhibitory potency and selectivity in vitro, with intracellular Stat3-inhibitory activity that
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is enhanced 2-3-fold. Analog S3I-201.1066 exhibited an
improved target selectivity and showed a minimum inhibitory
effect on the phosphorylation ofSrc, Jakl, Erkl/2MAPK and
She proteins at concentrations (30-50 µM) that inhibit intracellular Stat3 activation, despite there being SH2 domains
involved in the mechanisms leading to the activation of these
other proteins. Per molecular modeling, the improved activity
could in part be due to the enhanced interactions with the
Stat3 protein, possibly by the (para cyclohexyl)benzyl moiety
that extends from the scaffold amide nitrogen and makes
important contacts with the hydrophobic residues Trp623,
1 le659, Val637 and Phe716 within the unexplored pocket.
The native Stat3 peptide inhibitor, PpYLKTK (where pY
represents pTyr) and its peptidomimetic analogs (15,16) and
several other Stat3 SH2 domain-binding and dimerization
disrupting peptides and their derivatives have been reported
(21,22,25). Previous studies have utilized the fluorescence
polarization analysis to characterize the binding of the native,
high affinity phosphopeptide, GpYLPQTV-NH2 (as Scarboxyfluorescein-GpYLPQTV-NH2) to the Stat3 protein (22,
23 ). Using this assay platform and surface plasmon resonance
analysis, we provide definitive evidence forthe physical interaction ofS3I-201.1066 with Stat3 or its SH2 domain, with an
affinity (KD) of 2.3 µM.
The analysis of the interaction reveals a slower kinetics of
the association and dissociation, which contrasts the more
rapid binding and dissociation of the native, high affinity
peptide, GpYLPQTV-NH2 to and from Stat3, with a corresponding affinity (KD) of 24 nM. The implication of these
differences in the binding kinetics in relation to the modulation of Stat3 function is presently unclear.
The second supporting evidence for the interaction of
S3I201.1066 with Stat3 comes by way of the disruption by
S3I-201.1066 of the Stat3 binding to the pTyr peptide in a
fluorescent polarization assay based on the high affinity peptide, 5carboxyfluorescein-GpYLPQTV-NH2 probe and
Stat3, with a derived IC 50 of 45 µM.
By comparison, the unlabeled, native phosphopeptide disrupts this interaction between the probe and Stat3, with an
IC 50 value of 0.3 µM, which is in line with similar reported
studies of the high affinity peptide (22,23) that derived an
affinity of 0.15±0.01 µM (23) and an IC50 value of
0.290±0.063 µM (21). The higher affinity of the native peptide for the protein should be expected, given the more favorable physicochemical properties that will facilitate a stronger
binding to the Stat3 protein.
Overall, our study provides support for the binding of
S3I-201.1066 to Stat3, and for its ability to disrupt the interaction between Stat3 and its cognate pTyr peptide, an event
that is indicative of Stat3: Stat3 dimerization. Although other
Stat3 dimerization disruptors have been previously identified
through molecular modeling (19,45), the present study is the
first to provide biophysical evidence for a direct interaction of
a small-molecule, dimerization disruptor with the Stat3 protein. Given the disruption of the Stat3 binding to the cognate
peptide, GpYLPQTV-NH2, we infer that inside cells, S3I201.1066 may interfere with the ability of Stat3 (via SH2
domain) to bind to cognate pTyr motifs on receptors and
thereby block de nova phosphorylation by tyrosine kinases,
as well as disrupt pre-existing Stat3:Stat3 dimers, particularly
in malignant cells that harbor aberrant Stat3. Indeed, our
study shows a strong association of Stat3 with EGFR in
ligand-stimulated mouse fibroblasts or in cancer cells, and a
strong presence in the nucleus of stimulated cells. Both the
Stat3:EGFR association and the Stat3 nuclear presence are
blocked by S31201.1066, indicating that by disrupting Stat3

binding to receptors, S3I-201.1066 prevents Stat3 phosphorylation, activation, andnucleartranslocation, thereby attenuating Stat3 function.
Substantive evidence demonstrates that aberrant Stat3
activity promotes cancer cell growth and survival (15,16,29,
46,47), and induces tumor angiogenesis (48,49) and metastasis (43,49). Accordingly, inhibitors of Stat3 activation and
signaling have been shown to induce antitumor cell effects
consistent with the abrogation of Stat3 function (15-19,37,
50-52).
The present disclosure parallels these published reports in
showing that S3I-201.1066 induces growth inhibition and
loss of viability and survival of the human pancreatic cancer
Pane-I and breast cancer MDA-MB-231 cells, and of the
v-Src transformed mouse fibroblasts (NIH3T3/v-Src), which
are restricted to malignant cells that harbor aberrant Stat3,
while the effects on normal human pancreatic duct epithelial
cells, normal mouse fibroblasts, mouse thymic epithelial stromal cells, the viral Ras-transformed mouse fibroblasts that do
not harbor aberrant Stat3, and the Stat3 knockout mouse
embryonic fibroblasts (Stat3-/-) (31) are minimal.
Moreover, S3I-201.1066-induced antitumor cell effects
occurred at significantly lower concentrations, 30-50 µM,
than the 100 µM activity previously reported for the lead
agent (18). Mechanistic insight into the biological effects of
S3I-201.1066 as a Stat3 inhibitor is provided by the evidence
of a suppression of the constitutive expression of known
Stat3-regulated genes, including c-Myc, Bcl-xL, VEGF and
MMP-9, and the disruption of the Stat3 binding to receptor,
which control cell growth and apoptosis, promote tumor
angiogenesis, or modulate invasion (19,43,46,49,53,54). The
exclusion ofStat3 from the nucleus further contributes to the
inhibition of Stat3 transcriptional function. We further note
the significant antitumor effect of S3I-201.1066 in human
breast tumor xenografts. Altogether the present disclosure
provides evidence for the binding of S3I-201.1066 to Stat3,
disruption of Stat3:pTyr interactions and hence Stat3:Stat3
dimerization, and the disruption of the Stat3 binding to receptor, phosphorylation and nuclear translocation.
Accordingly, in the drawings and specification there have
been disclosed typical preferred embodiments of the invention and although specific terms may have been employed, the
terms are used in a descriptive sense only and not for purposes
of limitation. The invention has been described in considerable detail with specific reference to these illustrated embodiments. It will be apparent, however, that various modifications and changes can be made within the spirit and scope of
the invention as described in the foregoing specification and
as defined in the appended claims.
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12. A compound according to formula 2 and salts thereof.

That which is claimed:
1. A compound according to formula 1 and salts thereof.

Formula 2
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2. The compound of claim 1, used in a pharmaceutical

composition acceptable for administration to a patient.
3. The compound of claim 1, used in a method of treatment
effective to inhibit a cancer cell by contacting the cell with
said compound.
4. The compound of claim 1, used in a method of treatment
effective to inhibit a human pancreatic cancer cell by contacting the cell with said compound.
5. The compound of claim 1, used in a method of treatment
effective to inhibit a human breast cancer cell by contacting
the cell with said compound.
6. The compound of claim 1, used in a method of treatment
effective to inhibit a cell characterized by an aberrant level of
Stat3 by contacting the cell with said compound.
7. The compound of claim 1, used to inhibit a cell characterized by an aberrant level of Stat3 by contacting the cell with
said compound so as to selectively bind Stat3.
8. The compound of claim 1, used to down-regulate expression of Stat3-regulated genes in a cell by contacting the cell
with said compound.
9. The compound of claim 1, used to selectively inhibit
Stat3-DNA binding activity in a cell by contacting the cell
with said compound.
10. The compound of claim 1, used to block Stat3 association with epidermal growth factor receptor in EGF-stimulated
fibroblasts by contacting the fibroblasts with said compound.
11. The compound of claim 1, used to inhibit tumor cells
dependent on aberrant Stat3-mediated oncogenesis by contacting the tumor cells with said compound so as to interfere
with Stat3 function.
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13. The compound of claim 12, used in a pharmaceutical
composition acceptable for administration to a patient.
14. The compound of claim 12, used in a method of treatment effective to inhibit a cancer cell by contacting the cell
with said compound.
15. The compound of claim 12, used in a method oftreatment effective to inhibit a human pancreatic cancer cell by
contacting the cell with said compound.
16. The compound of claim 12, used in a method of treatment effective to inhibit a human breast cancer cell by contacting the cell with said compound.
17. The compound of claim 12, used in a method of treatment effective to inhibit a cell characterized by an aberrant
level of Stat3 by contacting the cell with said compound.
18. The compound of claim 12, used to inhibit a cell characterized by an aberrant level of Stat3 by contacting the cell
with said compound so as to selectively bind Stat3.
19. The compound of claim 12, used to down-regulate
expression ofStat3-regulated genes in a cell by contacting the
cell with said compound.
20. The compound of claim 12, used to selectively inhibit
Stat3-DNA binding activity in a cell by contacting the cell
with said compound.
21. The compound of claim 12, used to block Stat3 association with epidermal growth factor receptor in EGF-stimulated fibroblasts by contacting the fibroblasts with said compound.
22. The compound of claim 12, used to inhibit tumor cells
dependent on aberrant Stat3-mediated oncogenesis by contacting the tumor cells with said compound so as to interfere
with Stat3 function.
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